Targeting integrins in hepatocellular carcinoma

Bibliography

• Kane RC, Farrell AT, Madabushi R, Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25
   PubMed Web of Science ®Google Scholar
• Plow EF, Haas TA, Zhang L, Ligand binding to integrins. J Biol Chem 2000;275:21785-8
   PubMed Web of Science ®Google Scholar
• Hughes PE, Pfaff M. Integrin affinity modulation. Trends Cell Biol 1998;8:359-64
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998;91:2645-57
   PubMed Web of Science ®Google Scholar
• Li R, Mitra N, Gratkowski H, Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science 2003;300:795-8
   PubMed Web of Science ®Google Scholar
• Carman CV, Springer TA. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr Opin Cell Biol 2003;15:547-56
   PubMed Web of Science ®Google Scholar
• Xiong JP, Stehle T, Diefenbach B, Crystal structure of the extracellular segment of integrin alphaVbeta3. Science 2001;294:339-45
   PubMed Web of Science ®Google Scholar
• Xiong JP, Stehle T, Zhang R, Crystal structure of the extracellular segment of integrin alphaVbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002;296:151-5
   PubMed Web of Science ®Google Scholar
• Coller BS. Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol 1986;103:451-6
   PubMed Web of Science ®Google Scholar
• Beer JH, Springer KT, Coller BS. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. Blood 1992;79:117-28
   PubMed Web of Science ®Google Scholar
• DeMali KA, Wennerberg K, Burridge K. Integrin signaling to the actin cytoskeleton. Curr Opin Cell Biol 2003;15:572-82
   PubMed Web of Science ®Google Scholar
• Price LS, Leng J, Schwartz MA, Bokoch GM. Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol Biol Cell 1998;9:1863-71
   PubMed Web of Science ®Google Scholar
• Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J 1999;18:578-85
   PubMed Web of Science ®Google Scholar
• del Pozo MA, Price LS, Alderson NB, Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J 2000;19:2008-14
   PubMed Web of Science ®Google Scholar
• Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998;10:220-31
   PubMed Web of Science ®Google Scholar
• Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998;140:1255-63
   PubMed Web of Science ®Google Scholar
• Soldi R, Mitola S, Strasly M, Role of alphaVbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999;18:882-92
   PubMed Web of Science ®Google Scholar
• De S, Razorenova O, McCabe NP, VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 2005;102:7589-94
   PubMed Web of Science ®Google Scholar
• Short SM, Boyer JL, Juliano RL. Integrins regulate the linkage between upstream and downstream events in G protein-coupled receptor signaling to mitogen-activated protein kinase. J Biol Chem 2000;275:12970-7
   PubMedGoogle Scholar
• Moro L, Venturino M, Bozzo C, Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J 1998;17:6622-32
   PubMed Web of Science ®Google Scholar
• Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-26
   PubMed Web of Science ®Google Scholar
• Zhou GF, Ye F, Cao LH, Zha XL. Over expression of integrin alpha 5 beta 1 in human hepatocellular carcinoma cell line suppresses cell proliferation in vitro and tumorigenicity in nude mice. Mol Cell Biochem 2000;207:49-55
   PubMedGoogle Scholar
• Palmer EL, Ruegg C, Ferrando R, Sequence and tissue distribution of the integrin alpha9 subunit, a novel partner of beta1 that is widely distributed in epithelia and muscle. J Cell Biol 1993;123:1289-97
   PubMed Web of Science ®Google Scholar
• Volpes R, van den Oord JJ, Desmet VJ. Integrins as differential cell lineage markers of primary liver tumors. Am J Pathol 1993;142:1483-92
   PubMed Web of Science ®Google Scholar
• Torimura T, Ueno T, Kin M, Coordinated expression of integrin alpha6beta1 and laminin in hepatocellular carcinoma. Hum Pathol 1997;28:1131-8
   PubMedGoogle Scholar
• Clement B, Rescan PY, Baffet G, Hepatocytes may produce laminin in fibrotic liver and in primary culture. Hepatology 1988;8:794-803
   PubMed Web of Science ®Google Scholar
• Le Bail B, Faouzi S, Boussarie L, Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver. J Pathol 1997;181:330-7
   PubMedGoogle Scholar
• Ozaki I, Yamamoto K, Mizuta T, Differential expression of laminin receptors in human hepatocellular carcinoma. Gut 1998;43:837-42
   PubMed Web of Science ®Google Scholar
• Masumoto A, Arao S, Otsuki M. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells. Hepatology 1999;29:68-74
   Google Scholar
• Giannelli G, Fransvea E, Bergamini C, Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res 2003;9:3684-91
   PubMedGoogle Scholar
• Bergamini C, Sgarra C, Trerotoli P, Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 2007;46:1801-9
   PubMedGoogle Scholar
• Giancotti FG, Ruoslahti E. Elevated levels of the alpha5beta1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990;60:849-59
   PubMed Web of Science ®Google Scholar
• Su JM, Gui L, Zhou YP, Zha XL. Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance. World J Gastroenterol 2002;8:613-18
   PubMed Web of Science ®Google Scholar
• Yao M, Zhou XD, Zha XL, Expression of the integrin alpha5 subunit and its mediated cell adhesion in hepatocellular carcinoma. J Cancer Res Clin Oncol 1997;123:435-40
   PubMedGoogle Scholar
• Zhao J, Zhai W, Zhang Y. Expression of integrin alpha5, beta1 subunit and fibronectin mRNAs in human hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 1998;27:94-8
   PubMedGoogle Scholar
• Wu Y, Zuo J, Ji G, Proapoptotic function of integrin beta3 in human hepatocellular carcinoma cells. Clin Cancer Res 2009;15:60-9
   PubMedGoogle Scholar
• Jaskiewicz K, Chasen MR. Differential expression of transforming growth factor alpha, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis. Anticancer Res 1995;15:559-62, 43
   PubMedGoogle Scholar
• Xu XR, Huang J, Xu ZG, Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001;98:15089-94
   PubMed Web of Science ®Google Scholar
• Varner JA, Emerson DA, Juliano RL. Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 1995;6:725-40
   PubMed Web of Science ®Google Scholar
• Fang Z, Fu Y, Liang Y, Increased expression of integrin beta1 subunit enhances p21WAF1/Cip1 transcription through the Sp1 sites and p300-mediated histone acetylation in human hepatocellular carcinoma cells. J Cell Biochem 2007;101:654-64
   PubMedGoogle Scholar
• Liang YL, Fu Y, Chen SG, Integrin beta1 subunit overexpressed in the SMMC-7721 cells regulates the promoter activity of p21CIP1 and enhances its transcription. FEBS Lett 2004;558:107-13
   PubMedGoogle Scholar
• Fang Z, Yao W, Fu Y, Increased integrin alpha5beta1 heterodimer formation and reduced c-Jun expression are involved in integrin beta1 overexpression-mediated cell growth arrest. J Cell Biochem 2010;109:383-95
   PubMedGoogle Scholar
• Carloni V, Romanelli RG, Mercurio AM, Knockout of alpha6beta1-integrin expression reverses the transformed phenotype of hepatocarcinoma cells. Gastroenterology 1998;115:433-42
   PubMedGoogle Scholar
• Kikkawa Y, Sudo R, Kon J, Laminin alpha5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule. Exp Cell Res 2008;314:2579-90
   PubMedGoogle Scholar
• Giannelli G, Bergamini C, Fransvea E, Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 2001;81:613-27
   PubMedGoogle Scholar
• Tang J, Wu YM, Zhao P, betaig-h3 interacts with alpha3beta1 integrin to promote adhesion and migration of human hepatoma cells. Exp Biol Med 2009;234:35-9
   Google Scholar
• Tian B, Li Y, Ji XN, Basement membrane proteins play an active role in the invasive process of human hepatocellular carcinoma cells with high metastasis potential. J Cancer Res Clin Oncol 2005;131:80-6
   PubMedGoogle Scholar
• Honma N, Genda T, Matsuda Y, MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest 2006;86:687-96
   PubMedGoogle Scholar
• Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010;11:97-105
   PubMed Web of Science ®Google Scholar
• Zhang H, Ozaki I, Mizuta T, Transforming growth factor-beta1-induced apoptosis is blocked by beta1-integrin-mediated mitogen-activated protein kinase activation in human hepatoma cells. Cancer Sci 2004;95:878-86
   PubMedGoogle Scholar
• Kim HP, Kim TY, Lee MS, TGF-beta1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27Kip1 CDK inhibitor in hepatoma cells replated on fibronectin. Biochim Biophys Acta 2005;1743:151-61
   PubMedGoogle Scholar
• Cai T, Lei QY, Wang LY, Zha XL. TGF-beta1 modulated the expression of alpha5beta1 integrin and integrin-mediated signaling in human hepatocarcinoma cells. Biochem Biophys Res Commun 2000;274:519-25
   PubMed Web of Science ®Google Scholar
• Giannelli G, Fransvea E, Marinosci F, Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002;161:183-93
   PubMed Web of Science ®Google Scholar
• Yang C, Zeisberg M, Lively JC, Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res 2003;63:8312-17
   PubMedGoogle Scholar
• Giannelli G, Bergamini C, Fransvea E, Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005;129:1375-83
   PubMed Web of Science ®Google Scholar
• Fransvea E, Mazzocca A, Antonaci S, Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009;49:839-50
   Google Scholar
• Matsuo M, Sakurai H, Ueno Y, Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Cancer Sci 2006;97:155-62
   PubMedGoogle Scholar
• Wang Z, Wang M, Carr BI. Integrin alpha5-induced EGFR activation by prothrombin triggers hepatocyte apoptosis via the JNK signaling pathway. J Cell Physiol 2008;216:551-7
   PubMedGoogle Scholar
• Torimura T, Ueno T, Kin M, Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins. Hepatology 2001;34:62-71
   PubMed Web of Science ®Google Scholar
• Choi S, Lee SA, Kwak TK, Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood 2009;113:1845-55
   PubMedGoogle Scholar
• Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010;9:804-20
   PubMed Web of Science ®Google Scholar
• Brooks PC, Stromblad S, Klemke R, Antiintegrin alphavbeta3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22
   PubMed Web of Science ®Google Scholar
• Gutheil JC, Campbell TN, Pierce PR, Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000;6:3056-61
   PubMed Web of Science ®Google Scholar
• Mulgrew K, Kinneer K, Yao XT, Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, AbegrinTM. Mol Cancer Ther 2006;5:3122-9
   PubMed Web of Science ®Google Scholar
• Landen CN, Kim TJ, Lin YG, Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 2008;10:1259-67
   PubMed Web of Science ®Google Scholar
• Delbaldo C, Raymond E, Vera K, Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008;26:35-43
   PubMed Web of Science ®Google Scholar
• McNeel DG, Eickhoff J, Lee FT, Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005;11:7851-60
   PubMed Web of Science ®Google Scholar
• Trikha M, Zhou Z, Nemeth JA, CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110:326-35
   PubMed Web of Science ®Google Scholar
• Chen Q, Manning CD, Millar H, CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis 2008;25:139-48
   PubMed Web of Science ®Google Scholar
• Martin PL, Jiao Q, Cornacoff J, Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res 2005;11:6959-65
   PubMed Web of Science ®Google Scholar
• Ning S, Nemeth JA, Hanson RL, Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther 2008;7:1569-78
   PubMed Web of Science ®Google Scholar
• Mullamitha SA, Ton NC, Parker GJ, Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 2007;13:2128-35
   PubMed Web of Science ®Google Scholar
• Chen Q, Millar HJ, McCabe FL, alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin Cancer Res 2007;13:3689-95
   PubMedGoogle Scholar
• Vater CA, Manning C, Millar H, Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models. 20th EORTC-NCI-AACR symposium [abstract 529]. Mol Targets Cancer Ther EJC Suppl 2008;6(12): 167
   Google Scholar
• A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors. Bethesda, MD: clinicaltrials.gov, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00721669 [Last accessed 26 January 2011]
   Google Scholar
• Mitjans F, Meyer T, Fittschen C, In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000;87:716-23
   PubMed Web of Science ®Google Scholar
• A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer. Bethesda, MD: clinicaltrials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00958477 [Last accessed 26 January 2011]
   Google Scholar
• EMD 525797 in Colorectal & Ovarian Cancer Patients With Liver Metastases. Bethesda, MD: clinicaltrials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00848510 [Last accessed 26 January 2011]
   Google Scholar
• EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wildtype Metastatic Colorectal Cancer. Bethesda, MD: clinicaltrials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT01008475 [Last accessed 26 January 2011]
   Google Scholar
• Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-62
   PubMed Web of Science ®Google Scholar
• Yazji S, Bukowski R, Kondagunta V, Figlin R. Final results from phase II study of volociximab, an alpha5beta1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25: abstract 5094
   Google Scholar
• Ramakrishnan V, Bhaskar V, Law DA, Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006;5:273-86
   PubMedGoogle Scholar
• Ricart AD, Tolcher AW, Liu G, Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a Phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008;14:7924-9
   PubMed Web of Science ®Google Scholar
• Barton J. A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2008. J Clin Oncol 2008;26(20 Suppl 15S):9051
   Google Scholar
• A safety study of a monoclonal antibody against A5B1 integrin in solid tumors. Bethesda, MD: clinicaltrials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00915278 [Last accessed 26 January 2011]
   Google Scholar
• Erdreich-Epstein A, Tran LB, Cox OT, Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways. Blood 2005;105:4353-61
   PubMedGoogle Scholar
• Smith JW, Ruggeri ZM, Kunicki TJ, Cheresh DA. Interaction of integrins alphavbeta3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J Biol Chem 1990;265:12267-1271
   PubMedGoogle Scholar
• Nabors LB, Mikkelsen T, Rosenfeld SS, Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651-7
   PubMed Web of Science ®Google Scholar
• MacDonald TJ, Taga T, Shimada H, Preferential susceptibility of brain tumors to the antiangiogenic effects of an alphav integrin antagonist. Neurosurgery 2001;48:151-7
   PubMed Web of Science ®Google Scholar
• Yamada S, Bu XY, Khankaldyyan V, Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006;59:1304-12; discussion 1312
   PubMed Web of Science ®Google Scholar
• Burke PA, DeNardo SJ, Miers LA, Cilengitide targeting of alphavbeta3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72
   PubMed Web of Science ®Google Scholar
• Beekman KW, Colevas AD, Cooney K, Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 2006;4:299-302
   PubMed Web of Science ®Google Scholar
• MacDonald TJ, Stewart CF, Kocak M, Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26:919-24
   PubMed Web of Science ®Google Scholar
• Eskens FA, Dumez H, Hoekstra R, Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003;39:917-26
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T, Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-17
   PubMed Web of Science ®Google Scholar
• Stupp R, Goldbrunner R, Neyns B, Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). ASCO Annual Meeting Proceedings 2007. J Clin Oncol 2007;25(Part I 18S): abstract 2000
   Google Scholar
• Khalili P, Arakelian A, Chen G, A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006;5:2271-80
   PubMed Web of Science ®Google Scholar
• Cianfrocca ME, Kimmel KA, Gallo J, Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94:1621-6
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Sugi NH, Semba T, Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res 2002;62:6116-23
   PubMed Web of Science ®Google Scholar
• Semba T, Funahashi Y, Ono N, An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clin Cancer Res 2004;10(4):1430-8
   PubMedGoogle Scholar
• Mita MM, Mita AC, Ricart A, Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006. J Clin Oncol 2006;24(18S): abstract 3048
   Google Scholar
• A Phase II study of the safety and efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors. Bethesda, MD: clinicaltrials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00309179 [Last accessed 26 January 2011]
   Google Scholar
• FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer. Bethesda, MD: clinicaltrials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01133990 [Last accessed 26 January 2011]
   Google Scholar
• Huang TF, Sheu JR, Teng CM, Triflavin, an antiplatelet Arg-Gly-Asp-containing peptide, is a specific antagonist of platelet membrane glycoprotein Iib–IIIa complex. J Biochem 1991;109:328-34
   PubMed Web of Science ®Google Scholar
• Sheu JR, Lin CH, Chung JL, Triflavin, an Arg-Gly-Asp-containing antiplatelet peptide inhibits cell-substratum adhesion and melanoma cell-induced lung colonization. Jpn J Cancer Res 1992;83:885-93
   PubMedGoogle Scholar
• Sheu JR, Lin CH, Huang TF. Triflavin, an antiplatelet peptide, inhibits tumor cell-extracellular matrix adhesion through an arginine-glycine-aspartic acid-dependent mechanism. J Lab Clin Med 1994;123:256-63
   PubMed Web of Science ®Google Scholar
• Sheu JR, Lin CH, Peng HC, Huang TF. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells. Proc Soc Exp Biol Med 1996;213:71-9
   PubMed Web of Science ®Google Scholar
• Wu ZZ, Li P, Huang QP, Inhibition of adhesion of hepatocellular carcinoma cells to basement membrane components by receptor competition with RGD- or YIGSR-containing synthetic peptides. Biorheology 2003;40:489-502
   PubMed Web of Science ®Google Scholar
• Qian J, Yin J, Liang H, Experimental study on transarterial administration of GRGDSP combined with transarterial chemoembolization in rats with hepatic carcinoma. Cardiovasc Intervent Radiol 2008;31:377-82
   PubMedGoogle Scholar
• Fujii H, Nishikawa N, Komazawa H, A new pseudo-peptide of Arg-Gly-Asp (RGD) with inhibitory effect on tumor metastasis and enzymatic degradation of extracellular matrix. Clin Exp Metastasis 1998;16:94-104
   PubMedGoogle Scholar
• Ohnishi Y, Fujii H, Murakami K, A new pseudo-peptide analogue of the Arg-Gly-Asp (RGD) sequence inhibits liver metastasis of colon 26-L5 carcinoma cells. Cancer Lett 1998;124:157-63
   PubMedGoogle Scholar
• Tsuchiya Y, Sawada S, Tsukada K, Saiki I. A new pseudo-peptide of Arg-Gly-Asp (RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Int J Oncol 2002;20:319-24
   PubMedGoogle Scholar
• Zhang GM, Yang Y, Huang B, Experimental study on therapeutic effect of in vivo expression of Cell I-Hep II recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma. World J Gastroenterol 2003;9:1940-5
   PubMedGoogle Scholar
• Liu Y, Huang B, Yuan Y, Inhibition of hepatocarcinoma and tumor metastasis to liver by gene therapy with recombinant CBD-HepII polypeptide of fibronectin. Int J Cancer 2007;121:184-92
   PubMedGoogle Scholar
• Gong W, Liu Y, Huang B, Recombinant CBD-HepII polypeptide of fibronectin inhibits alphavbeta3 signaling and hematogenous metastasis of tumor. Biochem Biophys Res Commun 2008;367:144-9
   PubMed Web of Science ®Google Scholar
• Sudhakar A, Sugimoto H, Yang C, Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alphavbeta3 and alpha5beta1 integrins. Proc Natl Acad Sci USA 2003;100:4766-71
   PubMed Web of Science ®Google Scholar
• Maeshima Y, Colorado PC, Torre A, Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275:21340-8
   PubMed Web of Science ®Google Scholar
• Goto T, Ishikawa H, Matsumoto K, Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis. Int J Oncol 2008;33:33-40
   PubMedGoogle Scholar
• Hansma AH, Broxterman HJ, van der Horst I, Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol 2005;16:1695-701
   PubMed Web of Science ®Google Scholar
• Eder JP Jr, Supko JG, Clark JW, Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-84
   PubMed Web of Science ®Google Scholar
• Second-line therapy study of combined chemotherapy and endostar to patients with Non-Small Cell Lung Cancer(NSCLC). Bethesda, MD: clinicaltrials.gov, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00813332 [Last accessed 26 January 2011]
   Google Scholar
• Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer. Bethesda, MD: clinicaltrials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00842491 [Last accessed 26 January 2011]
   Google Scholar
• Synergistic treatment for Hepatocellular Carcinoma (HCC) using TACE with Antiangiogenesis (TACE HCC) Bethesda, MD: clinicaltrials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00518557 [Last accessed 26 January 2011]
   Google Scholar
• Li J, Tan H, Dong X, Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig Liver Dis 2007;39:557-65
   Google Scholar
• Liu Z, Wang J, Yin P, RGD-FasL induces apoptosis in hepatocellular carcinoma. Cell Mol Immunol 2009;6:285-93
   PubMedGoogle Scholar
• Brooks PC, Montgomery AM, Rosenfeld M, Integrin alphavbeta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64
   PubMed Web of Science ®Google Scholar
• Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 1992;10:111-20
   PubMed Web of Science ®Google Scholar
• Li X, Regezi J, Ross FP, Integrin alphavbeta3 mediates K1735 murine melanoma cell motility in vivo and in vitro. J Cell Sci 2001;114:2665-72
   PubMedGoogle Scholar
• Zheng DQ, Woodard AS, Fornaro M, Prostatic carcinoma cell migration via alphavbeta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999;59:1655-64
   PubMed Web of Science ®Google Scholar
• Albelda SM, Mette SA, Elder DE, Integrin distribution in malignant melanoma: association of the beta3 subunit with tumor progression. Cancer Res 1990;50:6757-64
   PubMed Web of Science ®Google Scholar
• Gasparini G, Brooks PC, Biganzoli E, Vascular integrin alphavbeta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-34
   PubMed Web of Science ®Google Scholar
• Weinel RJ, Rosendahl A, Neumann K, Expression and function of VLA-alpha2, -alpha3, -alpha5 and -alpha6-integrin receptors in pancreatic carcinoma. Int J Cancer 1992;52:827-33
   PubMed Web of Science ®Google Scholar
• Cress AE, Rabinovitz I, Zhu W, Nagle RB. The alpha6beta1 and alpha6beta4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995;14:219-28
   PubMed Web of Science ®Google Scholar
• Stallmach A, von Lampe B, Matthes H, Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. Gut 1992;33:342-46
   PubMed Web of Science ®Google Scholar
• Reynolds AR, Hart IR, Watson AR, Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009;15:392-400
   PubMed Web of Science ®Google Scholar
• Alghisi GC, Ponsonnet L, Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 2009;4:e4449: published online 12 February 2009, doi:10.1371/journal.pone.0004449
   Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
   PubMed Web of Science ®Google Scholar
• Sroka TC, Pennington ME, Cress AE. Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5. Carcinogenesis 2006;27:1748-57
   PubMedGoogle Scholar
• DeRoock IB, Pennington ME, Sroka TC, Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. Cancer Res 2001;61:3308-13
   PubMedGoogle Scholar
• Eble JA, Bruckner P, Mayer U. Vipera lebetina venom contains two disintegrins inhibiting laminin-binding beta1 integrins. J Biol Chem 2003;278:26488-96
   Google Scholar
• Iwamoto Y, Robey FA, Graf J, YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987;238:1132-4
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Iwahana M, Tanaka NG, Osada Y. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res 1991;51:903-6
   PubMed Web of Science ®Google Scholar
• Nakai M, Mundy GR, Williams PJ, A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 1992;52:5395-9
   PubMed Web of Science ®Google Scholar
• Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alphavbeta3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991;88:1924-32
   PubMed Web of Science ®Google Scholar
• A pilot study of adjuvant therapy of gefitinib (Iressa, ZD1839) in patients with Resectable Hepatocellular Carcinoma. Bethesda, MD: clinicaltrials.gov, 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00282100 [Last accessed 26 January 2011]
   Google Scholar
• Giannelli G, Azzariti A, Fransvea E, Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells. Br J Cancer 2004;91:1964-9
   PubMed Web of Science ®Google Scholar
• Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008;47:1557-66
   PubMed Web of Science ®Google Scholar
• Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 2009;277:114-20
   PubMed Web of Science ®Google Scholar
• Xu Y, Tabe Y, Jin L, TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 2008;142:192-201
   PubMed Web of Science ®Google Scholar